Related Experiment Video
Updated: Jun 13, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
[Selective internal radiotherapy (SIRT) for hepatocellular carcinoma]
G Antoch1, S P Mueller, M Hamami
1Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Universitätsklinik Essen, Universität Duisburg-Essen. gerald.antoch@uni-due.de
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|April 21, 2010
Summary
Microsphere radioembolization offers a new locoregional therapy for liver tumors, previously only treatable with systemic therapy. This review covers indications, techniques, and outcomes for this advanced interventional oncology treatment.
Area of Science:
- Interventional Oncology
- Radiopharmaceutical Therapy
- Hepatobiliary Malignancies
Context:
- Locoregional therapy for liver tumors is advancing with microsphere-based treatments.
- Systemic therapy was the primary option for diffuse or multifocal liver tumors.
- Radioembolization provides a targeted approach to liver cancer treatment.
Purpose:
- To review the indications for microsphere radioembolization.
- To describe the technique of intrahepatic radioactive microsphere delivery.
- To discuss the therapeutic results of microsphere radioembolization in liver cancer.
Summary:
- Microsphere radioembolization involves intrahepatic delivery of radioactive microspheres via the hepatic artery.
- This technique offers a locoregional treatment option for diffuse or multifocal liver tumors.
- Yttrium-90 glass or resin microspheres are the current standard for selective internal radiotherapy.
Impact:
- Microsphere radioembolization expands treatment options for liver cancer patients.
- This therapy provides an alternative to systemic treatments for specific liver tumor types.
- Advances in interventional oncology are improving outcomes for liver malignancies.
